{"url_path":"/sec/zbio/8-k/2026-05-13/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 **","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1953926/0001104659-26-059700-index.html","accession_number":"0001104659-26-059700","cik":"0001953926","ticker":"ZBIO","issuer_name":"Zenas BioPharma, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1953926/0001104659-26-059700-index.html","primary_entity_key":"0001953926","primary_entity_name":"Zenas BioPharma, Inc."},"word_count":136,"has_tables":true,"body_markdown":"**Item 5.07**\n**Submission of Matters to a Vote of Security Holders.**\n\n \n\nAt the Annual Meeting, the stockholders of the Company voted on the\nfollowing proposals:\n\n \n\n**Proposal One**: The stockholders elected each of the two nominees\nlisted below as Class II directors to serve on the Company’s Board of Directors for a term of three years expiring at the Company’s\n2029 Annual Meeting of Stockholders and until their successors are duly elected and qualified, based on the following votes:\n\n \n\nDirector Nominee \nFor  \nAgainst  \nAbstain  \nBroker\nNon-Votes \n\nJames Boylan \n 44,083,930  \n 4,121,508  \n 2,499  \n 4,458,184 \n\nPatrick Enright \n 44,253,715  \n 3,951,474  \n 2,748  \n 4,458,184 \n\n \n\n**Proposal Two**: The stockholders ratified the appointment of Ernst\n& Young LLP as the Company’s independent registered public accounting firm for its fiscal year ending December 31, 2026, based\non the following votes:\n\n \n\nFor  \nAgainst  \nAbstain \n\n52,654,975  \n7,650  \n3,496"}